Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer
The treatment options for patients with head-and-neck squamous cell carcinoma (HNSCC) are limited when the disease progresses after taking platinum, a PD-1 inhibitor, and cetuximab. To develop new agents for managing such pretreated malignancies, therapies targeting carcinogenic pathways could be po...
I tiakina i:
| Ngā kaituhi matua: | , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Wolters Kluwer Medknow Publications
2023-04-01
|
| Rangatū: | Journal of Cancer Research and Practice |
| Ngā marau: | |
| Urunga tuihono: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-22-00018 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|